Arcadia Biosciences schedules annual meeting for December 19, 2025

Arcadia Biosciences, Inc. (NASDAQ:RKDA), trading at $4.14 and showing impressive momentum with a 68% gain over the past six months, announced Friday that its 2025 annual meeting of stockholders is scheduled for December 19, 2025. According to InvestingPro data, analysts have set a $12 price target for the stock, suggesting significant upside potential. The company stated that the time, location, and agenda for the meeting will be detailed in its definitive proxy statement to be filed with the Securities and Exchange Commission.

The company noted that the 2025 annual meeting date differs by more than 30 days from the anniversary of its 2024 annual meeting. As a result, Arcadia Biosciences is informing stockholders about updated deadlines for submitting director nominations and proposals for inclusion in the proxy statement or for consideration at the meeting. Stockholders must ensure that any such proposals or nominations are received in writing by the close of business on November 3, 2025, at the company’s Dallas, Texas office, in accordance with SEC rules and the company’s bylaws.

Arcadia Biosciences clarified that the 2025 annual meeting and its related proxy statement are separate from any special meeting concerning the previously announced Securities Exchange Agreement with Roosevelt Resources, LP. The company reiterated that no offer or solicitation regarding the proposed transaction with Roosevelt Resources is being made through this filing.

According to the company, the submission of a stockholder proposal does not guarantee inclusion in the proxy materials or consideration at the meeting. Notices must comply with the procedures and content requirements set forth in the company’s bylaws.

This information is based on a press release statement included in the company’s recent filing with the Securities and Exchange Commission.

In other recent news, Arcadia Biosciences announced the resignation of its Chief Financial Officer, Mark Kawakami, effective September 12. Kawakami’s departure is not related to any disagreements with the company or its auditors concerning operations or financial practices. Following his resignation, Arcadia’s board appointed Thomas J. Schaefer as the Interim Chief Financial Officer. Schaefer, who is also the company’s President and Chief Executive Officer, will take on this additional role without any changes to his compensation. Schaefer previously held the CFO position from January 2023 until he became President and CEO in July 2024. The company has confirmed there are no familial ties between Schaefer and any other executive or director. Additionally, Kawakami has expressed his willingness to remain available as an advisor or consultant after his resignation. These developments reflect recent changes in Arcadia Biosciences’ executive team.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.